Treating Diabetes with Glucagon Like Peptide 1 Agonists: A Promising Therapeutic Approach
Glucagonlike peptide agonists

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as promising therapeutic options for addressing Type‐2 diabetes, obesity, and related conditions. Among these, semaglutide, tirzepatide, liraglutide etc., all notable GLP‐1RA, have gained attention owing to their favourable pharmacological properties and clinical efficacy.

The rise of glucagon-like peptide-1 (GLP‑1) receptor agonists (GLP‑1 RAs) such as semaglutide and tirzepatide has transformed modern metabolic medicine. Once used primarily for type 2 diabetes, these drugs are now prescribed widely for obesity, cardiometabolic risk reduction, and metabolic dysfunction more broadly.1 Their effectiveness has been described as unprecedented,2 with some ...
Key Details About Translated Article Glucagon Like Peptide 1 Agonists For Treating

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ago...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic options for addressing Type-2 diabetes, obesity, and related conditions. Among these, semaglutide, tirzepatide, liraglutide etc., all notable GLP-1RA, have gained attention owing to their favourable pharmacological properties and clinical efficacy. Aims

Useful Notes on Translated Article Glucagon Like Peptide 1 Agonists For Treating
Abstract Glucagon-like peptide-1 receptor agonists , or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity. More recently, it has become clear that these receptors are widely distributed throughout the central nervous system (CNS), which has raised the possibility of repurposing these drugs for neurological disorders.
With the advent of novel glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, and the discovery of their protective benefit against both adverse cardiovascular and kidney outcomes in large randomized clinical trials (RCTs),1 there has been intense interest in prescribing these...

Safety and Tolerability of Glucagon
Glucagon-like peptide-1 receptor agonists (GLP-1RAs)—along with the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA tirzepatide—are widely acknowledged for their efficacy in managing both type 2 diabetes mellitus and obesity, with expanding indications in cardiometabolic risk reduction. While their glycemic, weight-lowering, and cardiovascular benefits are well established ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in neurodegeneration through intermediate, aetiology-agnostic pathways, likely involving metabolic, inflammatory and several other relevant neurobiological ...

Prescribing Trends of Glucagon
This cross-sectional study examines the US prescribing trends of glucagon-like peptide 1 (GLP-1) receptor agonists among individuals with type 2 diabetes and/or obesity.









The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types ...